ASBMR Three Year Pre-Meeting Symposia

美国骨与矿物质研究协会（ASBMR）是美国最大的专业、科学和医学研究机构， 一个社会建立，汇集临床和实验室为基础的科学家谁是参与研究 骨、矿物质和肌肉骨骼科学，有举办年度专题会议的成功历史 自2002年以来，由NIH R13赠款资助。最近，ASBMR收到了两个，三年的R13赠款 涵盖2016-2018年和2019-2021年会前专题讨论会计划。目前的申请寻求资金 一个为期三年的R13赠款，以推进肌肉骨骼疾病领域的重点放在三个具体领域 2022年、2023年和2024年的科学研究：1）“罕见疾病：从分子和机制到 治疗学”; 2）“骨细胞在骨骼健康和疾病中的作用以及作为治疗靶细胞”; 3）“能量 代谢在骨骼发育和疾病”。这三个专题讨论会涵盖以下高度相关的领域： 肌肉骨骼研究最近经历了科学知识的快速发展， 导致严重的临床发病率、残疾率和死亡率。R13的总体目标是刺激 进一步的进步，将导致改善病人护理的肌肉骨骼疾病， 三个专题讨论会的最佳研究人员。研讨会将审查每个主题领域的最新技术， 与与会者交流思想，并促进年轻和成熟的研究人员之间的互动。 鼓励研讨会与会者参加随后的ASBMR年会， 与肌肉骨骼研究人员互动的机会。所有三个专题讨论会的方案都是由 组委会和前两次研讨会的所有发言人都已确认参加。 演讲者包括成立和年轻的研究人员，妇女和男子，而且，由于大约一半的ASBMR 会员来自美国以外，一些重要的国际演讲者也被邀请。海报 会议，年轻的研究者颁奖典礼，并在每次会议结束时的“晚餐”之夜是 计划促进年轻调查人员与资深发言人之间的直接互动。2022年 研讨会将聚集国际罕见骨病专家，讨论基础研究的最新进展， 机制和疗法，为临床医生提供如何识别它们的指导，以及从 罕见疾病直接应用于骨质疏松症等更常见的骨骼疾病。2023年 研讨会将回顾在基础，转化和临床研究的进展，骨细胞的作用， 骨的生物学和病理生理学，以及如何以治疗目标靶向骨细胞。骨细胞在 机械生物学、激素作用、骨肿瘤及骨细胞内分泌作用等。2024年 研讨会将讨论能量代谢在骨骼发育中的作用的最新进展， 疾病;包括缺氧的作用和呼吸道介导的机制，及其参与 骨对合成代谢治疗和代谢疾病（如糖尿病）的反应。

The American Society for Bone and Mineral Research (ASBMR), the largest professional, scientific and medical society established to bring together clinical and laboratory-based scientists who are involved in the study of bone, mineral and musculoskeletal science, has had a successful history of conducting annual topical meetings funded by single year NIH R13 grants since 2002. More recently, ASBMR received two, three-year R13 grants to cover pre-meeting symposia programs for 2016-2018 and 2019-2021. The current application seeks funding for a three-year R13 grant to advance the field of musculoskeletal diseases by focusing on three specific areas of scientific research in 2022, 2023 and 2024: 1) “Rare Diseases: From Molecules and Mechanisms to Therapeutics”; 2) “Osteocytes in Bone Health and Disease and as Therapeutic Target Cells”; 3) “Energy Metabolism in Skeletal Development and Disease”. These three symposia cover highly relevant areas of musculoskeletal research that has recently undergone rapid evolution in scientific knowledge and collectively contribute to major clinical morbidity disability and mortality. The overall objective of this R13 is to stimulate further advances that will result in improved patient care for musculoskeletal diseases by bringing together the best researchers for each of the three symposia. The symposia will review the state of the art in each topic area, exchanging ideas with attendees, and stimulating the interaction between young and established researchers. Symposia attendees will be encouraged to attend the subsequent ASBMR Annual Meetings for additional opportunities to interact with musculoskeletal researchers. Programs for all three symposia were developed by an organizing committee, and all speakers for the first two symposia have confirmed their participation. Presenters include established and young investigators, women and men, and, since about half of ASBMR membership is from outside the US, a number of key international speakers have also been invited. Poster sessions, young investigator award presentations, and at the end of each meeting a “dine-around” evening are planned to promote direct interaction between young investigators and more senior speakers. In 2022, the symposium will gather international experts in rare bone diseases to discuss the latest advances on underlying mechanisms and therapies, provide guidance to clinicians on how to recognize them, and lessons learnt from rare diseases that have direct application to more common bone diseases such as osteoporosis. In 2023, the symposium will review the advances in basic, translational and clinical research on the role of osteocytes in the biology and pathophysiology of bone, and how to target osteocytes with therapeutic goals. The osteocyte role in mechanobiology, hormone actions, cancer in bone and osteocyte endocrine actions will be discussed. The 2024 symposium will discuss the recent advances on the role of energy metabolism in skeletal development and disease; including the role of hypoxia and mitochondria-mediated mechanisms, and its involvement in the response of bone to anabolic therapies and metabolic diseases such as diabetes.